International Women's Day 8 March: LKF conducts research on women's health with women leading the way

Kiel and Hamburg, Germany, and Vienna, Austria, 06 March 2020 - LKF - Laboratorium für Klinische Forschung GmbH, a subsidiary of GBA Group Pharma, is honouring International Women's Day on 8 March 2020 by highlighting the company's female success factors.

"Every day is Women's Day at LKF," says Bärbel Wilke, co-founder and CEO of LKF, with 80 percent of its 150 employees being women. Many of the 120 female employees working in the three-storey laboratory are highly qualified specialists and scientists from the fields of chemistry, biology, molecular biology et al.

When the medical-technical assistant Bärbel Wilke started analysing blood counts together with Prof. Dr. Wolfgang Junge in 1991, she benefited from the fact that, as the mother of a three-year-old son, she was able to work mostly at night. "Flexibility is not only essential for working mothers, it is also what our customers value most about us. It's in our DNA," says Wilke. For example, LKF not only offers 30 different family-friendly working time models, but also the highest degree of flexibility towards the customer. A recipe for success that has paid off. Since its founding in 1991, LKF has recorded continuous revenue growth of 10-15 percent per year.

Numerous studies in the field of women's health
From planning to execution, the broad range of services offered by LFK today covers all aspects of the laboratory part of clinical studies. One of the focal points is the area of Women's Health. "The improvement of women's health is a central research field of the pharmaceutical industry, which we have successfully supported for many years," says Bärbel Wilke. In addition to contraception and hormone replacement therapy, this includes in-vitro fertilisation (unfulfilled desire to have children) and osteoporosis therapy.

"Due to the extensive hormone studies, we offer a very large list of specific coagulation parameters. The background here is the potential risk of thrombosis," said Wilke. In the field of menstrual blood quantification, LKF offers a comprehensive solution worldwide.

LFK also has many years of experience in endometriosis studies, a disease in which tissue similar to the lining of the uterus is grows outside the uterus. In Germany alone, for example, about 7-15 percent of all women of reproductive age are affected every month. In other countries, the disease rate is up to 20 percent.

Women in the lead
"Thanks to their expertise, women play an extremely important role in the success of LKF as well as of other companies in our group," explains Dr. Elisabeth Lackner, CEO of the parent company GBA Group Pharma. "It is no surprise that three of our subsidiaries, Pharmacelsus, GBA Pharma Labs and LKF, are managed by female CEOs."

About LKF
LKF - Laboratorium für Klinische Forschung GmbH, based in Kiel, is part of GBA Group Pharma and supports Phase I - IV clinical trials. Within its global network of partner laboratories in North and Latin America, India, China and Australia, LKF offers worldwide laboratory services for clinical trials. All data is gathered in a central database in Kiel, from where it is sent to doctors worldwide.

LKF has established a strict quality management system based on the international guidelines GCP and ISO 17025. Sustainability also plays an important role. LKF has been EcoVadis certified since 2016.

About GBA Group Pharma
GBA Group Pharma, as part of GBA, is a unique service provider for the international pharmaceutical and biotech industry with 6 sites in Austria and Germany. GBA Group Pharma offers preclinical (Pharmacelsus) and analytical laboratory services (GBA Pharma Labs), and with its central clinical laboratory (LKF) in combination with ABF, a full service provider for clinical trial products (IMP), comprehensive services and expertise for development and approved drugs.
GBA Group Pharma employs around 500 people in Austria, Germany and the UK.
GBA Group Pharma is part of the GBA Group (Hamburg, Germany).

For further information please contact:

GBA Group Pharma
Natalie Eiffe-Kuhn
Mobile: 13
Email:

Media and Investor Relations
MC Services AG
Julia Hofmann
T 0
Email: